List view / Grid view
10 March 2014 | By Merck
Move reinforces business strategy to reach a minimum of 3% total share per key market and at least 3 leading brands in investment markets...
10 March 2014 | By Waters
2014 Honor marks fourth time in last ten years Waters' has been recognized by Pittcon Media Corps...
10 March 2014 | By Rigaku
Rigaku Raman Technologies announced its next generation handheld analyzer, the Rigaku Progenyä, designed from the ground up to deliver the industry’s most comprehensive and accurate materials identification, and improved ease of use, adaptability and reliability...
10 March 2014 | By Teva
Teva Pharmaceuticals USA and Volunteers in Medicine announced their 2014 National Partnership to make healthcare services more readily available to the uninsured...
7 March 2014 | By Roche
Diagnostics division strengthens its position in the serology market and expands its immunoassay portfolio in infectious disease...
7 March 2014 | By Novartis
Novartis announced that a pivotal Phase III trial of Jakavi® (ruxolitinib) compared to best available therapy has met its primary endpoint of maintaining hematocrit control...
7 March 2014 | By Daiichi Sankyo Company
Daiichi Sankyo Company, Limited announced in August 2011 that the group company Kitasato Daiichi Sankyo Vaccine Company, Limited was selected for the Japanese Ministry of Health, Labour and Welfare's cell culture vaccine production facility capacity building grant...
6 March 2014 | By Sanofi
At its meeting held on March 5, 2014, the Board of Directors of Sanofi proposed the appointment of Patrick Kron as a new independent Director...
6 March 2014 | By Novartis
Novartis announced that the European Commission has approved the use of Xolair® as an add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent patients...
6 March 2014 | By Boehringer Ingelheim
More than 100 countries have now approved Boehringer Ingelheim’s Pradaxa® for the prevention of stroke and systemic embolism for adult patients with the most common sustained heart rhythm condition...
5 March 2014 | By Roche
Roche presented new data from the LUTE / VERSE phase IIb studies investigating lebrikizumab in patients with severe uncontrolled asthma...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting…
5 March 2014 | By Biogen Idec
Agreement to enhance R&D capabilities and pipeline aimed at creating new therapies to suppress Alzheimer’s disease progression...
5 March 2014 | By Freeman Technology
Powder characterisation specialists from Freeman Technology will be at PITTCON 2014 where the company is exhibiting the FT4 Powder Rheometer®...
4 March 2014 | By Roche
Roche announced that its Ordinary Annual General Meeting has voted in favour of all of the Board of Directors’ proposals...
